Literature DB >> 8707268

Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance.

D C Rockey1, R A Weisiger.   

Abstract

Hepatic stellate cells are similar to tissue pericytes and have been shown to be contractile. In this study, we examined the effects of known mediators of stellate cell contraction on portal pressure in rat livers after carbon tetrachloride induced injury (including cirrhosis) and investigated the contractility of stellate cells as a function of liver injury. Sarafotoxin S6C, an endothelin B (ETB) receptor agonist, had minor effects on portal pressure when perfused into normal livers at concentrations known to elicit stellate cell contraction (2 nmol/L). In contrast, both endothelin-1 (2 nmol/L) and angiotensin II (8.6 nmol/L) caused a rapid and pronounced rise in portal pressure. The effects of sarafotoxin S6C (a potent stellate cell contractile agonist) on portal pressure were greater in cirrhotic than normal liver, whereas those of angiotensin II were unchanged after liver injury. Endothelin-1 and sarafotoxin S6C induced contractility of stellate cells increased in proportion to the degree of liver injury. Contractility was greatest for stellate cells isolated from cirrhotic livers, a population of cells that displayed the most activated phenotype, as measured by immunoblot of smooth muscle alpha actin. Autoradiography of cirrhotic livers after perfusion with 125I-endothelin-1 revealed binding to cells in both sinusoidal spaces and collagenous fibrotic bands, consistent with known locations of stellate cells. Finally, the mixed endothelin-A (ETA) and ETB receptor antagonist, bosentan, reduced portal pressure in portal hypertensive animals, consistent with its inhibitory effect on stellate cell contraction. We conclude that stellate cell contractility increases with progressive liver injury and is proportional to the degree of stellate cell activation, becoming most prominent in the cirrhotic liver. Endothelin-stimulated contraction of stellate cells in cirrhotic liver may contribute to increased intrahepatic resistance and portal pressure.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707268     DOI: 10.1002/hep.510240137

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  70 in total

Review 1.  Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease.

Authors:  J Vlachogiannakos; A K Tang; D Patch; A K Burroughs
Journal:  Gut       Date:  2001-08       Impact factor: 23.059

Review 2.  Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.

Authors:  H Reynaert; M G Thompson; T Thomas; A Geerts
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

3.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

4.  Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis.

Authors:  Lan Qin; Yuan-Ping Han
Journal:  Am J Pathol       Date:  2010-09-16       Impact factor: 4.307

5.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

6.  NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.

Authors:  S Fiorucci; E Antonelli; O Morelli; A Mencarelli; A Casini; T Mello; B Palazzetti; D Tallet; P del Soldato; A Morelli
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

Review 7.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

8.  Synaptophysin: A novel marker for human and rat hepatic stellate cells.

Authors:  D Cassiman; J van Pelt; R De Vos; F Van Lommel; V Desmet; S H Yap; T Roskams
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

9.  Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats.

Authors:  Yao Hong Wei; Li Jun; Chen Ji Qiang
Journal:  Dig Dis Sci       Date:  2004-10       Impact factor: 3.199

10.  Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease.

Authors:  Hong-Qiang Feng; Nate D Weymouth; Don C Rockey
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-19       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.